Alivus Life Sciences Limited

₹1,559As of Sun 8 Nov 2026, 12:00 UTC
NSE:ALIVUSHealthcare
Country India
PE (Fwd) •••
TSR 5Y CAGR 20.09%
Div yield 0.32%
ROE 20.15%
Drug Manufacturers (Specialty & Generic)
Beta (5Y) 0.05
PE TTM 28.64
TSR TTM 72.95%
Mkt cap ₹191.4B
ROIC 24.02%
SE Grade™
Value
Quality
Moat
Consensus
Reference
₹1,568
0.58%
(91.06%)
Hold 1|2|4|11|12
3Q26
4Q26
1Q27
2Q27
Earnings per share₹
30.10
30.06
33.42
33.24
(5.19%)
(2.02%)
13.82%
13.88%
Revenue₹B
10.62
10.62
10.40
10.91
15.61%
12.83%
4.88%
6.93%
Peers (US$1.924B)
Cap (US$)
PE
1.926B
13.11x
Capital
TTM
5Y
10Y
Leveragex
0.792
0.141
0.115
EBIT/Intx
2.017
0.223
0.198
Own earn%
(69.41)
15.82
5.32
Sh yield%
7.07
31.49
35.95
Owners
Insiders/Inst%
4.69
72.23
Short interest%
4.92
SBC / revenue%
3.35
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
0
Op margin range%
7–16
$1 testx
0.1
Incr. ROIC%
37